Eflucimibe Pierre Fabre/Eli Lilly

Current Opinion in Investigational Drugs

Volumn 4, Issue 3, 2003, Pages 347-351

  Burnett, John R ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2,6 DIISOPROPYL) 3 [[1 [4 (DIMETHYLAMINO)PHENYL]CYCLOPENTYL]METHYL]UREA; 2,2 DIMETHYL N (2,4,6 TRIMETHOXYPHENYL)DODECANAMIDE; ANTILIPEMIC AGENT; ATORVASTATIN; AVASIMIBE; CHOLESTEROL ACYLTRANSFERASE INHIBITOR; CP 113818; EFLUCIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LECIMIBIDE; UNCLASSIFIED DRUG;

ADRENAL DISEASE; ATHEROSCLEROSIS; CLINICAL TRIAL; DOSE RESPONSE; DRUG ADSORPTION; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG POTENCY; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG SELECTIVITY; DRUG SPECIFICITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; HYPERCHOLESTEROLEMIA; IC 50; NONHUMAN; REVIEW; SIDE EFFECT; STRUCTURE ACTIVITY RELATION; TOXICOKINETICS;

ANILIDES; ANIMALS; ANTICHOLESTEREMIC AGENTS; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; CORONARY ARTERIOSCLEROSIS; HUMANS; HYPERCHOLESTEROLEMIA; STEROL O-ACYLTRANSFERASE;

EID: 0037740964     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (21)

1. 133037 Subacute toxicity of a novel inhibitor of acyl-CoA: Cholesterol acyltransferase in beagle dogs. Dominick MA, McGuire EJ, Reindel JF, Bobrowski WF, Bocan TM, Gough AW Fundam Appl Toxicol 1993 20 2 217-224
2. 231207 Difference between normal and WHHL rabbits in susceptibility to the adrenal toxicity of an acyl-CoA: Cholesterol acyltransferase inhibitor, FR145237. Matsuo M, Hashimoto M, Suzuki J, Iwanami K, Tomoi M, Shimomura K Toxicol Appl Pharmacol 1996 140 2 387-392
3. 246571 Fabre sets up in UK to launch Navelbine. Scrip 1997 2231 13
4. 399986 Drug development pipeline - Eptapirone, F-12511, F-11782, donitriptan, KpOMpA, F-50077, F-50008, F-50003, F-50000, F-50028, F-2692, F-12682. Pierre Fabre SA Company Communication 2001 February 23
5. 407413 Lack of toxic effects of F 12511, a novel potent inhibitor of acylcoenzyme A:cholesterol O-acyltransferase, on human adrenocortical cells in culture. Junquero D, Pilon A, Carilla-Durand E, Patoiseau J-F, Tarayre J-P, Torpier G, Staels B, Fruchart J-C, Colpaert FC, Clavey V, Delhon A Biochem Pharmacol 2001 61 4 387-398 Report of the preclinical safety evaluation of eflucimibe in the NCI-H295R cell line (which has functional comparable to those of normal human adrenal cells), showing lack of toxic effects.
6. 407414 Overexpression of SR-BI in hamsters treated with a novel ACAT inhibitor (F12511). Milliat F, Ferezou J, Delhon A, Lutton C C R Acad Sci Ser III 2001 324 3 229-234 Describes the decreased absorption coefficient of dietary cholesterol and the increased expression of hepatic SR-BI in eflucimibe-treated hamsters.
7. 407415 F 12511, a novel ACAT inhibitor, and atorvastatin regulate endogenous hypercholesterolemia in a synergistic manner in New Zealand rabbits fed a casein-enriched diet. Junquero D, Bruniquel F, N'Guyen X, Autin JM, Patoiseau JF, Degryse AD, Colpaert FC, Delhon A Atherosclerosis 2001 155 1 131-142 Eflucimibe is 3- to 4-fold more potent than atorvastatin in reducing total plasma cholesterol. When co-administered, the agents lowered plasma total cholesterol and apoB-100-containing lipoproteins to a greater extent and more rapidly than either agent alone.
8. 407416 Pharmacological profile of F 12511, (S)-2′,3′,5′-trimethyl-4′-hydroxy-α-dodecylthioace tanilide a powerful and systemic acylcoenzyme A: Cholesterol acyltransferase inhibitor. Junquero D, Oms P, Carilla-Durand E, Autin J, Tarayre JP, Degryse AD, Patoiseau JE, Colpaert FC, Delhon A Biochem Pharmacol 2001 61 1 97-108 Describes the pharmacological profile of eflucimibe, lipid-lowering effects in small animal models and a preclinical safety evaluation of eflucimibe in guinea pigs, showing minimal adrenal toxicity.
9. 408118 Lilly and bioMerieux-Pierre fabre to collaborate on ACAT inhibitor for atherosclerosis. Eli Lilly & Co Press Release 2001 May 03
10. 440367 Anti-atherosclerotic properties of the acyl-coenzyme A: Cholesterol acyltransferase inhibitor F-12511 in casein-fed New Zealand rabbits. Rival Y, Junquero D, Bruniquel F, N'Guyen X, Faure P, Promies JP, Degryse AD, Delhon A J Cardiovasc Pharmacol 2002 39 2 181-191 Lipid lowering by eflucimibe reduces the incidence of vascular lesions and macrophage infiltration and may reinforce the fibrous skeleton of the atheroma.
11. 463571 Avasimibe (Pfizer). Burnett JR, Huff MW Curr Opin Investig Drugs 2002 3 9 1328-1333
12. 477157 Crystalline polymorphism of eflucimibe. Ribet JP, Pena R, Chauvet A, Patoiseau JF, Autin JM, Segonds R, Basquin M, Autret JM Ann Pharm Fr 2002 60 3 177-186 Identifies and describes two crystalline polymorphic forms of eflucimibe using differential scanning calorimetry, X-ray powder diffraction from synchrotron radiation, infrared spectrometry, and solid-state nuclear magnetic resonance spectrometry.
13. 479679 Acyl coenzyme A:cholesterol acyltransferase inhibition and hepatic apolipoprotein B secretion. Burnett JR, Wilcox LJ, Huff MW Clin Chim Acta 1999 286 1-2 231-242
14. 480706 Role of acyl-CoA:cholesterol acyltransferase in cellular cholesterol metabolism. Suckling KE, Stange EF J Lipid Res 1985 26 6 647-671
15. 480707 Acyl-coenzyme A:cholesterol acyltransferase. Chang TY, Chang CCY, Cheng D Annu Rev Biochem 1997 66 613-638
16. 480708 Immunodepletion experiments suggest that acyl-coenzyme A:cholesterol acyltransferase-1 (ACAT1) protein plays a major catalytic role in adult human liver, adrenal gland, macrophages, and kidney, but not in intestines. Lee O, Chang CCY, Lee W, Chang TY J Lipid Res 1998 39 8 1722-1727
17. 480709 Identification of a form of acyl-CoA:cholesterol acyltransferase specific to liver and intestine in nonhuman primates. Anderson RA, Joyce C, Davis M, Reagan JW, Clark M, Shelness G, Rudel LL 1998 273 41 26747-26754
18. 480711 Morphogenesis of a zone-specific adrenocortical cytotoxicity in guinea pigs administered PD132301-2, an inhibitor of acyl-coA:cholesterol acyltransferase. Dominick MA, Bobrowski WA, MacDonald JR, Gough AW Toxicol Pathol 1993 21 1 54-62
19. 480718 Hamsters predisposed to sucrose-induced cholesterol gallstones (LPN strain) are more resistant to excess dietary cholesterol than hamsters that are not sensitive to cholelithiasis induction. Souidi M, Combettes-Souverain M, Milliat F, Eckhardt ER, Audas O, Dubrac S, Parquet M, Ferezou J, Lutton C J Nutr 2001 131 6 1803-1811
20. 481165 Research and development: Presentation and figures. Pierre Fabre SA Company World Wide Web Site 2003 March 10
21. 481426 Drug development pipeline - Eflucimibe. Pierre Fabre SA Company Communication 2003 March 11